Wapnick Pamela sold $4K of MGX
Wapnick Pamela (Chief Financial Officer) sold 2,884 shares of Metagenomi Therapeutics, Inc. (MGX) at $1.30 on 2026-06-05.
How this was made
The 30-second read
Why it matters
The only new fact is the CFO’s open-market sale of 2,884 shares at $1.2990 on June 5; it does not include guidance, trial results, or regulatory updates.
Market read
Traders may note the insider-sale datapoint, but the small dollar value and lack of accompanying corporate news make it unlikely to drive a sustained repricing.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but the disclosed size ($3.7k) is small, reducing interpretive power.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Metagenomi Therapeutics, Inc.
Ticker impact
Metagenomi Therapeutics CFO Wapnick Pamela sold 2,884 shares in an open-market transaction reported on SEC Form 4.
Low near-term impact; any reaction is likely muted unless paired with other company-specific catalysts.
Form 4 insider sales are common and this filing provides no new operational/regulatory/financial development beyond the sale details.
Market effects
No clear sector read-through from a small, routine insider sale.
None.
None.
Counterpoint
If the sale is part of a broader pattern (multiple recent insider sales), it could reinforce bearish positioning despite the lack of new fundamentals.
Key entities
- issuerMetagenomi Therapeutics, Inc.
Company whose insider transaction is disclosed (MGX).
- insiderWapnick Pamela
Chief Financial Officer reporting the sale.
